COMPANY PROFILE // THE 014 REPORT
Phibro Animal Health Corp.
PAHC (Nasdaq) · Formerly: PHILIPP BROTHERS CHEMICALS INC
Assembled from 4 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber3 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-06-26: a pattern of leadership change.
✓ SEC filings✓ SAM registrationpossible match✓ State registrationpossible match✗ LEI✗ IRS return✗ Website✗ Lobbying registration
No LEI, no IRS return, no website, no lobbying registration on record.
PHIBRO ANIMAL HEALTH CORP is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Teaneck, NJ; listed as PAHC (Nasdaq).[source] It reported revenue of $1.52 billion for the fiscal year ended 2026-06-30.[source] It has filed 88 documents with the SEC in the last 12 months; the latest is Form 8-K, filed 2026-11-04.[source] Its largest institutional holders on 13F filings are BlackRock, Inc., FMR LLC, STATE STREET CORP (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 3 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-06-26.[source]
- red0
- amber1
- info0
- BlackRock, Inc.$101.1M
- FMR LLC$99.2M
- STATE STREET CORP$32.6M
- MILLENNIUM MANAGEMENT LLC$29.4M
- VANGUARD CAPITAL MANAGEMENT LLC$29.0M
- GEODE CAPITAL MANAGEMENT, LLC$20.6M
- DIMENSIONAL FUND ADVISORS LP$16.7M
- VANGUARD PORTFOLIO MANAGEMENT LLC$16.0M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Andolino Anthony · See Remarks (Officer) · latest Form 4 2025-08-19 · filing · LinkedIn search
- BENDHEIM JACK · President and CEO (Director,Officer,10% owner) · latest Form 4 2026-03-31 · filing · LinkedIn search
- Bendheim Daniel M · Exec. VP, Corporate Strategy (Director,Officer) · latest Form 4 2025-08-19 · filing · LinkedIn search
- David Glenn · Chief Financial Officer (Officer) · latest Form 4 2026-02-11 · filing · LinkedIn search
- Escudero Lisa Ann · See Remarks (Officer) · latest Form 4 2025-08-19 · filing · LinkedIn search
- Miller Larry Lee · Chief Operating Officer (Officer) · latest Form 4 2025-08-19 · filing · LinkedIn search
- Rodriguez Patrick · VP Finance and Treasurer (Officer) · latest Form 3 2026-01-22 · filing · LinkedIn search
- Weinstein Judith · See Remarks (Officer) · latest Form 4 2025-08-19 · filing · LinkedIn search
- BENDHEIM Jonathan · Director · latest Form 4 2025-08-19 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001069899 | source |
| UEIpossible match | GJL5KLKJC3D1 | source |
| CAGEpossible match | 5R956 | source |
| EIN | 13-1840497 | source |
| NY DOS ID | 4842140 | record |
| Business address (SEC) | GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., SUITE 21, TEANECK, NJ, 07666 | source |
Does not exist in the records we hold: LEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-01-09 · in 48 days · SAM registration expires (UEI GJL5KLKJC3D1)possible match
- 2027-02-09 · in 79 days · Next 10-Q due (period ended 2026-12-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-08-29 · in 280 days · Next 10-K due (period ended 2027-06-30; Large accelerated filer) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
Federal contractors nearby in the same code (2)
- PHIBRO ANIMAL HEALTH CORPORATION · SAM Active
- GC BIOPHARMA USA, INC. · SAM Active
registered in SAM.gov with the same ZIP code (07666) and the same primary NAICS code (325412), extract 2026-11-01
EVERY SOURCE · NEWEST FIRST
One timeline
- 2027-01-09 registration SAM registration expiry (UEI GJL5KLKJC3D1) · SAM.gov
- 2026-11-04 filing 8-K items 2.02,5.07,9.01 · SEC EDGAR
- 2026-11-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-03 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-09-18 filing ARS · SEC EDGAR
- 2026-09-18 filing DEFA14A · SEC EDGAR
- 2026-09-18 filing Proxy statement · SEC EDGAR
- 2026-09-16 filing 144 · SEC EDGAR
- 2026-08-26 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-26 filing Annual report (10-K) · SEC EDGAR
- 2026-08-04 filing 144 · SEC EDGAR
- 2026-08-04 filing 144 · SEC EDGAR
- 2026-08-04 filing 144 · SEC EDGAR
- 2026-08-04 filing 144 · SEC EDGAR
- 2026-08-04 filing 144 · SEC EDGAR
- 2026-08-04 filing 144 · SEC EDGAR
- 2026-07-28 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-06-26 officer change 8-K items 5.02 · SEC EDGAR
- 2026-06-16 filing 144 · SEC EDGAR
- 2026-05-22 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-05-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-05-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-05 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-04-30 filing 8-K items 1.01,2.03,9.01 · SEC EDGAR
- 2026-04-27 filing 8-K items 7.01,9.01 · SEC EDGAR
- 2026-04-23 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-04-14 officer change 8-K items 5.02 · SEC EDGAR
- 2026-03-13 filing 144 · SEC EDGAR
- 2026-02-11 filing 144 · SEC EDGAR
- 2026-02-04 filing 8-K items 2.02,9.01 · SEC EDGAR
170 earlier entries
- 2026-02-04 filing Quarterly report (10-Q)
- 2026-02-03 filing 8-K items 8.01,9.01
- 2026-01-22 insider First Form 3/4/5 on record for Rodriguez Patrick (VP Finance and Treasurer)
- 2025-12-18 officer change 8-K items 5.02,7.01,9.01
- 2025-12-15 filing SCHEDULE 13D/A
- 2025-12-04 filing 144
- 2025-11-05 filing 8-K items 2.02,5.07,9.01
- 2025-11-05 filing Quarterly report (10-Q)
- 2025-11-04 filing 8-K items 8.01,9.01
- 2025-09-19 filing ARS
- 2025-09-19 filing DEFA14A
- 2025-09-19 filing Proxy statement
- 2025-09-04 filing 144
- 2025-08-27 filing 8-K items 2.02,9.01
- 2025-08-27 filing Annual report (10-K)
- 2025-08-19 filing 144
- 2025-08-19 insider First Form 3/4/5 on record for Andolino Anthony (See Remarks)
- 2025-08-19 insider First Form 3/4/5 on record for BENDHEIM JACK (President and CEO)
- 2025-08-19 insider First Form 3/4/5 on record for Bendheim Daniel M (Exec. VP, Corporate Strategy)
- 2025-08-19 insider First Form 3/4/5 on record for David Glenn (Chief Financial Officer)
- 2025-08-19 insider First Form 3/4/5 on record for Escudero Lisa Ann (See Remarks)
- 2025-08-19 insider First Form 3/4/5 on record for Miller Larry Lee (Chief Operating Officer)
- 2025-08-19 insider First Form 3/4/5 on record for Weinstein Judith (See Remarks)
- 2025-08-19 insider First Form 3/4/5 on record for BENDHEIM Jonathan (Director)
- 2025-07-29 filing 8-K items 8.01,9.01
- 2025-06-03 filing SCHEDULE 13D/A
- 2025-05-19 filing 144
- 2025-05-07 filing 8-K items 2.02,9.01
- 2025-05-07 filing Quarterly report (10-Q)
- 2025-05-06 filing 8-K items 8.01,9.01
- 2025-02-18 filing 144
- 2025-02-05 filing 8-K items 2.02,9.01
- 2025-02-05 filing Quarterly report (10-Q)
- 2025-02-04 filing 8-K items 8.01,9.01
- 2025-01-23 officer change 8-K items 5.02,9.01
- 2025-01-07 filing 8-K/A items 9.01
- 2024-11-15 filing SC 13D/A
- 2024-11-12 officer change 8-K items 5.02
- 2024-11-06 filing 8-K items 2.02,5.07,9.01
- 2024-11-06 filing Quarterly report (10-Q)
- 2024-11-05 filing 8-K items 8.01,9.01
- 2024-10-31 filing 8-K items 2.01,2.03,7.01,9.01
- 2024-09-20 filing ARS
- 2024-09-20 filing DEFA14A
- 2024-09-20 filing Proxy statement
- 2024-08-28 filing 8-K items 2.02,9.01
- 2024-08-28 filing Annual report (10-K)
- 2024-08-13 filing 144
- 2024-07-30 filing 8-K items 8.01,9.01
- 2024-07-09 filing 8-K items 1.01,2.03,9.01
- 2024-05-13 filing 144
- 2024-05-08 filing 8-K items 2.02,9.01
- 2024-05-08 filing Quarterly report (10-Q)
- 2024-05-07 filing 8-K items 8.01,9.01
- 2024-04-29 filing 8-K items 1.01,7.01,9.01
- 2024-03-05 filing 144
- 2024-02-14 filing SC 13D/A
- 2024-02-07 filing 8-K items 2.02,9.01
- 2024-02-07 filing Quarterly report (10-Q)
- 2024-02-06 filing 8-K items 8.01,9.01
- 2024-02-06 officer change 8-K items 5.02,7.01,9.01
- 2023-12-05 filing 144
- 2023-11-08 filing 8-K items 2.02,9.01
- 2023-11-08 filing Quarterly report (10-Q)
- 2023-11-07 filing 8-K items 5.07
- 2023-11-07 filing 8-K items 7.01,9.01
- 2023-11-06 filing 8-K items 8.01,9.01
- 2023-09-15 filing ARS
- 2023-09-15 filing DEFA14A
- 2023-09-15 filing Proxy statement
- 2023-09-05 filing 144
- 2023-09-05 officer change 8-K items 5.02,7.01,9.01
- 2023-08-30 filing 8-K items 2.02,9.01
- 2023-08-30 filing Annual report (10-K)
- 2023-07-25 filing 8-K items 8.01,9.01
- 2023-07-06 officer change 8-K items 5.02
- 2023-06-16 filing 8-K items 1.01,2.03,9.01
- 2023-06-08 filing SC 13D/A
- 2023-05-03 filing 8-K items 2.02,9.01
- 2023-05-03 filing Quarterly report (10-Q)
- 2023-05-01 filing 8-K items 8.01,9.01
- 2023-02-08 filing 8-K items 2.02,9.01
- 2023-02-08 filing Quarterly report (10-Q)
- 2023-02-06 officer change 8-K items 5.02,8.01,9.01
- 2022-12-16 filing SC 13D/A
- 2022-11-09 filing 8-K items 2.02,9.01
- 2022-11-09 filing Quarterly report (10-Q)
- 2022-11-08 filing 8-K items 5.07
- 2022-11-07 filing 8-K items 8.01,9.01
- 2022-09-16 filing DEFA14A
- 2022-09-16 filing Proxy statement
- 2022-08-24 filing 8-K items 2.02,9.01
- 2022-08-24 filing Annual report (10-K)
- 2022-07-25 filing 8-K items 8.01,9.01
- 2022-05-25 filing SC 13D/A
- 2022-05-04 filing 8-K items 2.02,9.01
- 2022-05-04 filing Quarterly report (10-Q)
- 2022-05-02 filing 8-K items 8.01,9.01
- 2022-02-09 filing 8-K items 2.02,9.01
- 2022-02-09 filing Quarterly report (10-Q)
- 2022-02-07 filing 8-K items 8.01,9.01
- 2022-01-12 filing 8-K items 7.01,9.01
- 2021-11-02 filing 8-K items 5.07
- 2021-11-02 filing 8-K items 2.02,9.01
- 2021-11-02 filing Quarterly report (10-Q)
- 2021-11-01 filing 8-K items 8.01,9.01
- 2021-09-17 filing DEFA14A
- 2021-09-17 filing Proxy statement
- 2021-08-25 filing 8-K items 2.02,9.01
- 2021-08-25 filing Annual report (10-K)
- 2021-07-26 filing 8-K items 8.01,9.01
- 2021-06-25 filing SC 13D/A
- 2021-05-06 filing 8-K items 2.02,9.01
- 2021-05-06 filing Quarterly report (10-Q)
- 2021-05-03 filing 8-K items 8.01,9.01
- 2021-04-22 filing 8-K items 1.01,2.03,9.01
- 2021-02-03 filing 8-K items 2.02,9.01
- 2021-02-03 filing Quarterly report (10-Q)
- 2021-02-01 filing 8-K items 8.01,9.01
- 2020-12-15 filing SC 13D/A
- 2020-11-04 filing 8-K items 2.02,9.01
- 2020-11-04 filing Quarterly report (10-Q)
- 2020-11-03 filing 8-K items 5.07
- 2020-11-02 filing 8-K items 8.01,9.01
- 2020-09-18 filing DEFA14A
- 2020-09-18 filing Proxy statement
- 2020-09-17 officer change 8-K items 5.02,9.01
- 2020-08-26 filing 8-K items 2.02,9.01
- 2020-08-26 filing Annual report (10-K)
- 2020-07-27 filing 8-K items 8.01,9.01
- 2020-07-17 filing 8-K items 7.01,9.01
- 2020-06-08 filing SC 13D/A
- 2020-05-07 filing 8-K items 2.02,9.01
- 2020-05-07 filing Quarterly report (10-Q)
- 2020-05-04 filing 8-K items 8.01,9.01
- 2020-02-12 officer change 8-K items 5.02
- 2020-02-03 filing 8-K items 2.02,8.01,9.01
- 2020-02-03 filing Quarterly report (10-Q)
- 2019-12-20 filing SC 13D/A
- 2019-11-05 filing 8-K items 5.07
- 2019-11-04 filing 8-K items 2.02,8.01,9.01
- 2019-11-04 filing Quarterly report (10-Q)
- 2019-09-20 filing DEFA14A
- 2019-09-20 filing Proxy statement
- 2019-08-27 filing 8-K items 2.02,9.01
- 2019-08-27 filing Annual report (10-K)
- 2019-08-01 filing 8-K items 1.01,7.01,9.01
- 2019-07-29 filing 8-K items 8.01,9.01
- 2019-06-26 filing SC 13D/A
- 2019-05-10 officer change 8-K items 5.02
- 2019-05-06 filing 8-K items 2.02,8.01,9.01
- 2019-05-06 filing Quarterly report (10-Q)
- 2019-02-06 filing 8-K items 2.02,8.01,9.01
- 2019-02-06 filing Quarterly report (10-Q)
- 2018-11-19 filing CT ORDER
- 2018-11-06 filing 8-K items 2.02,5.07,9.01
- 2018-11-06 filing Quarterly report (10-Q)
- 2018-11-05 filing 8-K items 8.01,9.01
- 2018-09-21 filing DEFA14A
- 2018-09-21 filing Proxy statement
- 2018-09-17 filing SC 13D/A
- 2018-08-27 filing 8-K items 2.02,9.01
- 2018-08-27 filing Annual report (10-K)
- 2018-07-31 filing 8-K items 1.01
- 2018-07-30 filing 8-K items 8.01,9.01
- 2018-06-26 filing SC 13D/A
- 2018-05-07 officer change 8-K items 1.01,5.02,9.01
- 2018-05-07 filing 8-K items 2.02,8.01,9.01
- 2018-05-07 filing Quarterly report (10-Q)
- 2018-02-05 filing 8-K items 2.02,8.01,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-04 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-11-04 (within 30 days) 10-Q filed
- 2026-11-03 (within 30 days) 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-10-13 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 002)
- 2026-09-18 (older) ARS filed
- 2026-09-18 (older) DEFA14A filed
- 2026-09-18 (older) DEF 14A filed
- 2026-08-26 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:PAHC The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
7 possible matches held apart, matched by name only, not counted above; 1 record under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1069899 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | PAHC / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 131840497 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001069899 | SEC EDGAR / IRS |
| CUSIP | 71742Q106 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001069899 | SEC EDGAR |
| UEI | GJL5KLKJC3D1 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001069899 | USAspending |
possible match: matched by name only, not merged (5)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110064400946 (PHIBRO ANIMAL HEALTH CORP) | name-exact:legal-name: same registered legal name as 'PHIBRO ANIMAL HEALTH CORP' | EPA ECHO facilities |
| EPA FRS id | 110037416025 (PHIBRO ANIMAL HEALTH CORP) | name-exact:legal-name: same registered legal name as 'PHIBRO ANIMAL HEALTH CORP' | EPA ECHO facilities |
| EPA FRS id | 110070560229 (PHIBRO ANIMAL HEALTH CORP) | name-exact:legal-name: same registered legal name as 'PHIBRO ANIMAL HEALTH CORP' | EPA ECHO facilities |
| EPA FRS id | 110070638662 (PHIBRO ANIMAL HEALTH CORPORATION) | name-exact:legal-name: same registered legal name as 'PHIBRO ANIMAL HEALTH CORP' | EPA ECHO facilities |
| EPA FRS id | 110069357662 (PHIBRO ANIMAL HEALTH CORPORATION) | name-exact:legal-name: same registered legal name as 'PHIBRO ANIMAL HEALTH CORP' | EPA ECHO facilities |
former name (shown apart, not merged) (1)
- former namePHILIPP BROTHERS CHEMICALS, INCORPORATED · Connecticut business registrations
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2026-06-30) | $1,518,093,000 | 2026-06-30 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-22 00:38 UTC | Report an error |
| Net income (loss) (fiscal year ended 2026-06-30) | $99,720,000 | 2026-06-30 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 00:38 UTC | Report an error |
| Total assets (at 2026-06-30) | $1,501,241,000 | 2026-06-30 | 10-K, XBRL Assets | as filed | 2026-11-22 00:38 UTC | Report an error |
| Stockholders' equity (at 2026-06-30) | $385,477,000 | 2026-06-30 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 00:38 UTC | Report an error |
| Cash and cash equivalents (at 2026-06-30) | $61,419,000 | 2026-06-30 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 00:38 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-22 00:38 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-22 00:38 UTC | Report an error |
| State of incorporation | DE | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-22 00:38 UTC | Report an error |
| Fiscal year end (MMDD) | 0630 | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-22 00:38 UTC | Report an error |
| Business address | GLENPOINTE CENTRE EAST, 3RD FLOOR, 300 FRANK W. BURR BLVD., SUITE 21, TEANECK, NJ, 07666 | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-22 00:38 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-04 | SEC EDGAR company profile | as filed | 2026-11-22 00:38 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2026-06-30) | $68,954,000 | 2026-06-30 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 00:38 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2026-06-30) | $59,088,000 | 2026-06-30 | 10-K, XBRL PaymentsToAcquireProductiveAssets | as filed | 2026-11-22 00:38 UTC | Report an error |
| Operating lease liabilities (at 2026-06-30) | $55,973,000 | 2026-06-30 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 00:38 UTC | Report an error |
| Plan (pension, plan no. 002) | PHIBRO ANIMAL HEALTH CORPORATION 401(K) RETIREMENT AND SAVINGS PLAN: 1,292 participants, assets $218,681,573 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-22 00:38 UTC | Report an error |
| Plan (welfare, plan no. 501) | PHIBRO ANIMAL HEALTH CORPORATION HEALTH AND BENEFIT PLAN: 838 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-22 00:38 UTC | Report an error |
| Plan (welfare, plan no. 502) | PHIBRO ANIMAL HEALTH CORPORATION LIFE AND LTD BENEFIT PLAN: 1,009 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-22 00:38 UTC | Report an error |
| Federal award transactions, fiscal year 2026 (this one registration only) | $0 | 2026-09-30 | USAspending recipient profile | as filed | 2026-11-22 00:38 UTC | Report an error |
| Number of federal award transactions, fiscal year 2026 (this one registration only) | 1 | 2026-09-30 | USAspending recipient profile | as filed | 2026-11-22 00:38 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001104659-26-122692
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $386,774,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001104659-26-122692 | 2026-11-22 00:38 UTC | Report an error |
| Net income (loss) | $29,520,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001104659-26-122692 | 2026-11-22 00:38 UTC | Report an error |
| Interest expense | $12,251,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001104659-26-122692 | 2026-11-22 00:38 UTC | Report an error |
| Cash and cash equivalents | $75,548,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001104659-26-122692 | 2026-11-22 00:38 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-04 Filing 8-K filed: Item 2.02 results of operations; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-11-04 Filing 10-Q filed
- 2026-11-03 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-10-13 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 002)
- 2026-09-18 Filing ARS filed
- 2026-09-18 Filing DEFA14A filed
- 2026-09-18 Filing DEF 14A filed
- 2026-08-26 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-08-26 Filing 10-K filed
- 2026-07-28 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-06-26 Filing 8-K filed: Item 5.02 officer or director change
- 2026-06-25 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 501)
- 2026-06-25 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 502)
- 2026-05-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-06 Filing 10-Q filed
- 2026-05-05 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-04-30 Filing 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 9.01 exhibits
- 2026-04-27 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-04-14 Filing 8-K filed: Item 5.02 officer or director change
- 2026-02-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-02-04 Filing 10-Q filed
- 2026-02-03 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-12-18 Filing 8-K filed: Item 5.02 officer or director change; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-11-05 Filing 8-K filed: Item 2.02 results of operations; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2025-11-05 Filing 10-Q filed
6 earlier entries
- 2025-11-04 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2025-09-19 Filing ARS filed
- 2025-09-19 Filing DEFA14A filed
- 1989-07-01 Record plan effective date: PHIBRO ANIMAL HEALTH CORPORATION 401(K) RETIREMENT AND SAVINGS PLAN
- 1981-11-01 Record plan effective date: PHIBRO ANIMAL HEALTH CORPORATION HEALTH AND BENEFIT PLAN
- 1981-11-01 Record plan effective date: PHIBRO ANIMAL HEALTH CORPORATION LIFE AND LTD BENEFIT PLAN
8-K item text, as filed (excerpts)
- 2026-11-04 8-K Item 2.02, RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On November 4, 2026, Phibro Animal Health Corporation issued a press release announcing its operating results for the fiscal quarter ended September 30, 2026 and its financial guidance for the fiscal year ending June 30, 2027. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as… the 8-K · retrieved 2026-11-22 00:38 UTC - 2026-11-04 8-K Item 5.07, SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
On November 3, 2026, the Corporation held its annual meeting of stockholders (the “Meeting”). Present at the Meeting in person or by proxy were holders of 18,569,002 shares of Class A common stock of the Corporation and 19,496,034 shares of Class B common stock of the Corporation, which together represent 98.8% of the voting power of all shares of common stock of the Corporation as of September 11, 2026, the record date for the Meeting, and constituting a quorum for the transaction of business at the Meeting. The stockholders of the Corporation voted on the following items at the Meeting: 1. To elect three Class I Directors to serve until the 2029 annual meeting of stockholders and until… the 8-K · retrieved 2026-11-22 00:38 UTC - 2026-11-03 8-K Item 8.01
OTHER EVENTS On November 3, 2026, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 16, 2026, to stockholders of record at the close of business on November 25, 2026. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. the 8-K · retrieved 2026-11-22 00:38 UTC - 2026-08-26 8-K Item 2.02, RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On August 26, 2026, Phibro Animal Health Corporation issued a press release announcing its operating results for the fourth quarter and fiscal year ended June 30, 2026 and its financial guidance for the fiscal year ending June 30, 2027. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this report, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any filing under the Securities Act of… the 8-K · retrieved 2026-11-22 00:38 UTC - 2026-07-28 8-K Item 8.01
OTHER EVENTS On July 28, 2026, Phibro Animal Health Corporation issued a press release announcing the declaration of a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on September 23, 2026, to stockholders of record at the close of business on September 2, 2026. A copy of the press release announcing the dividend is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. the 8-K · retrieved 2026-11-22 00:38 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (5)
possible match: matched by name only, not merged (5)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPHIBRO ANIMAL HEALTH CORP · exact legal name · sx:epa:110064400946 Compare
- possible matchPHIBRO ANIMAL HEALTH CORP · exact legal name · sx:epa:110037416025 Compare
- possible matchPHIBRO ANIMAL HEALTH CORP · exact legal name · sx:epa:110070560229 Compare
- possible matchPHIBRO ANIMAL HEALTH CORPORATION · exact legal name · sx:epa:110070638662 Compare
- possible matchPHIBRO ANIMAL HEALTH CORPORATION · exact legal name · sx:epa:110069357662 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | $101,077,857 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:38 UTC | Report an error |
| 2 | FMR LLC | $99,232,821 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:38 UTC | Report an error |
| 3 | STATE STREET CORP | $32,605,195 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:38 UTC | Report an error |
| 4 | MILLENNIUM MANAGEMENT LLC | $29,412,411 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:38 UTC | Report an error |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $28,992,185 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:38 UTC | Report an error |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | $20,644,155 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:38 UTC | Report an error |
| 7 | DIMENSIONAL FUND ADVISORS LP | $16,677,205 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:38 UTC | Report an error |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | $15,966,460 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:38 UTC | Report an error |
| 9 | RENAISSANCE TECHNOLOGIES LLC | $15,087,700 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:38 UTC | Report an error |
| 10 | CastleKnight Management LP | $14,485,511 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:38 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPHIBRO ANIMAL HEALTH CORPORATION · exact legal name · sx:nydos:4842140 Compare
USAspending (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchPHIBRO ANIMAL HEALTH CORPORATION · exact legal name · sx:usaspending:GJL5KLKJC3D1 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1069899.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001069899. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.